Uchimoto, T.; Komura, K.; Fukuokaya, W.; Kimura, T.; Takahashi, K.; Yano, Y.; Nishimura, K.; Nakamori, K.; Fujiwara, Y.; Matsunaga, T.;
et al. Risk Classification for Overall Survival by the Neutrophil–Lymphocyte Ratio and the Number of Metastatic Sites in Patients Treated with Pembrolizumab—A Multicenter Collaborative Study in Japan. Cancers 2021, 13, 3554.
https://doi.org/10.3390/cancers13143554
AMA Style
Uchimoto T, Komura K, Fukuokaya W, Kimura T, Takahashi K, Yano Y, Nishimura K, Nakamori K, Fujiwara Y, Matsunaga T,
et al. Risk Classification for Overall Survival by the Neutrophil–Lymphocyte Ratio and the Number of Metastatic Sites in Patients Treated with Pembrolizumab—A Multicenter Collaborative Study in Japan. Cancers. 2021; 13(14):3554.
https://doi.org/10.3390/cancers13143554
Chicago/Turabian Style
Uchimoto, Taizo, Kazumasa Komura, Wataru Fukuokaya, Takahiro Kimura, Kazuhiro Takahashi, Yusuke Yano, Kazuki Nishimura, Keita Nakamori, Yuya Fujiwara, Tomohisa Matsunaga,
and et al. 2021. "Risk Classification for Overall Survival by the Neutrophil–Lymphocyte Ratio and the Number of Metastatic Sites in Patients Treated with Pembrolizumab—A Multicenter Collaborative Study in Japan" Cancers 13, no. 14: 3554.
https://doi.org/10.3390/cancers13143554
APA Style
Uchimoto, T., Komura, K., Fukuokaya, W., Kimura, T., Takahashi, K., Yano, Y., Nishimura, K., Nakamori, K., Fujiwara, Y., Matsunaga, T., Tsutsumi, T., Tsujino, T., Maenosono, R., Yoshikawa, Y., Taniguchi, K., Tanaka, T., Uehara, H., Hirano, H., Nomi, H.,
... Azuma, H.
(2021). Risk Classification for Overall Survival by the Neutrophil–Lymphocyte Ratio and the Number of Metastatic Sites in Patients Treated with Pembrolizumab—A Multicenter Collaborative Study in Japan. Cancers, 13(14), 3554.
https://doi.org/10.3390/cancers13143554
